The National Health Service cost regulators for England and Wales have recommended the use of Zytiga in the treatment of men with castrate resistant advanced prostate cancer. The National Institute for Health and Clinical Excellence (NICE) has published a final guidance endorsing Zytiga as an NHS treatment option for men with advanced, metastatic, castration resistant [...]
Many of us in the United States with advanced prostate cancer who have failed Zytiga are looking to enter the Early Access MDV-3100 Clinical Trial. However, you need to be aware that there are some requirements you will need to meet prior to starting MDV-3100. You will need to wait 30 days after stopping Zytiga [...]
I have heard some occasional discussion that once (that is if) enzalutamide (MDV-3100) is approved by the FDA for the treatment of men with advanced prostate cancer, it will over shadow Provenge. On the contrary, I believe that the approval of enzalutamide will actually encourage additional use of Provenge resulting in the increasing use of [...]
Yesterday, Johnson & Johnson announced that it has asked U.S. and European Union regulators to grant broader marketing approval for its cancer pill, Zytiga which is used to treat men with castrate resistant prostate cancer. Zytiga was approved in 2011 for the treatment of advanced prostate cancer in men who have received chemotherapy and who [...]
I have had a number of recent conversations with men with advanced prostate cancer who have been taking Abiraterone Acetate (Zytiga). The question that comes up in regular conversation is about knowing when Zytiga has stopped working or when Zytiga should be discontinued. All the real guidance we have to answer this question comes from [...]